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 Cytochrome P450 enzymes (P450s) are heme containing monooxygenases with 
great potential in applications focused in biotechnological areas. An understanding of the 
precise chemical process behind this enzyme is essential in research in the areas of 
pharmaceuticals and biochemistry. In order to get a better understanding of P450s, it is 
important to provide spectroscopic characterization of the electron spin distributions 
within the heme macrocycle. Paramagnetic NMR has been shown to be a powerful tool 
for probing electronic distribution and spin-densities within the heme macrocycle. 
Selective incorporation of 13C may facilitate the use of 13C-NMR in the study of P450 
monooxygenase. Furthermore, selective labeling with 15N or 2H at specific positions 
within the heme group maybe also be useful in the application of other spectroscopic 
techniques when applied to P450 enzymes. All of these labeling studies could be 
accomplished using a recombinant expression system involving a strain of E.coli which 
cannot produce aminolevulinic acid (ALA), a biosynthetic heme precursor. By 
synthesizing 2H, 13C or 15N labeled ALA, incorporation of these isotopes into the heme of 
dehaloperoxidase, a model heme protein, via the biosynthetic pathway of the heme 
cofactor maybe accomplished. A successfully method was developed to make 2H-ALA in 
a way that is both economical and time efficient, and the relative ability of this expression 
system to incorporate 2H into the heme was evaluated, relative to 13C or 15N. 
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CHAPTER I 
INTRODUCTION 
I.A. General overview of cytochrome P450 
 Iron serves important functions in the human body; therefore many important 
proteins contain heme as a prosthetic group, which means it contains an iron atom in the 
center of a large heterocyclic ring called a porphyrin. Cytochrome P450 (CYP450) is a 
diverse family of a metalloproteins containing a heme prosthetic group that is bound to 
the protein via thiolate ligation of a protein Cys residue1. CYP450 belongs to a group of 
monoxygenase enzyme that catalyzes many biological reactions in bacteria, plants and 
animals. It is also responsible for the metabolism of many endobiotic metabolisms such 
as testosterone, progesterone and they also play an important role in the xenobiotic 
metabolism in humans.  
There are the two general classes that P450 enzymes can be split into, class I, 
which consists of most bacterial P450s and class II, which includes mammalian P450s. 
Class I P450’s  are cytosolic in nature with a lot of applications focused in the field of 
biotechnology. Studies on microsomal P450s tend to aim at understand xenobiotic 
metabolism in humans which is a major component in the field of pharmacology. 
CYP450 has a big role in metabolism of pharmaceuticals and contribute to the
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 biotransformation of a biologically active parent compound2. This process generally 
leads to less active metabolites that are more easily eliminated from the body. 
The name cytochrome P450 has been given to this class due to the fact that these 
proteins all have reduced-CO complexes with an absorption peak with a λ max at 450 
nm1,2,3.  The CO binding pigment has a red shift when reduced and bound to CO whereas 
most heme proteins have a blue shift when reduced and bound to CO. In the reaction 
mechanism of P450 containing system, the active site of CYP450 contains a heme iron 
center. The reaction mechanism of the P450 family is a cyclic reaction that involves the 
reduction and oxidation of the central heme iron by incoming electrons, donated from 
nicotamide adenine dinucleotide phosphate (NADPH). The catalytic cycle of CYP450 is 
shown below in Figure I.1. The reaction takes place with the binding of a substrate to the 
active site which causes the heme to go from its ferric hexa-coordinated (low-spin) state 
to the ferric penta-coordinated (high spin) state. The second stage in the cycle is the 
reduction of the heme iron to the ferrous state by a single electron transfer from NADPH. 
In the third step, molecular oxygen binds rapidly to the metal center forming a Fe2+-O2 
complex, which undergoes a slow conversion to a more stable Fe3+-O2°
- complex. In the 
fourth step, there is a second reduction in which a second electron is accepted from the 
reductase and forms a ferric-peroxide complex, (Fe-O) 3+. This is a very unstable complex 
so in the next step, it is rapidly protonated and forms a hydroperoxo-ferric intermediate, 
which then is protonated again to release water and  produces a reactive oxo-ferryl 
intermediate. In the next step, a ferryl-oxo species reacts with substrate to form a 
2 
 
 
hydroxylated product. This product is released from the active site and replaced by the 
water2.  
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Figure I.1: The catalytic cycle of cytochrome P4502 
As indicated previously, the active site of P450 contains an iron protoporphyrin 
IX group where oxygen is activated and substrate oxidation occurs. The numbering 
system of heme and its structure is found below in Figure I.2. The dots on the figure 
represent the four meso positions and are labeled with Greek letters α, β, γ, and δ. The 
core carbons (located in the pyrrole rings) have a separate system of numbering. For 
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example, the first carbon away from the meso carbon (Cm) is called Cα and the second 
carbon away from the meso carbon is Cβ
4. Shown in figure below is an iron atom in 
center of protoporphyrin ring bound to four nitrogen atoms from the pyrrole rings. In the 
current work an attempt was made to label various positions on the heme with stable 
isotopes. 
 
Cmα 
Cmδ Cmβ 
Cα 
Cβ 
Cmγ 
Figure I.2: Structure and numbering of protoheme IX4  
I.B. Escherichia coli Hu227 and dehaloperoxidase 
 Our attempts to label the heme in P450 involve utilization of a specialized strain 
of E.Coli. Hu227 strain is a mutant strain which contains a mutation in the HemeA gene, 
which codes for the enzyme glutamyl-tRNA (GTA) reductase11. GTA reductase is 
responsible for the reduction of glutamyl-tRNA to glutamyl-1-semialdehyde (GSA). The 
next reaction by GSA – aminotransferase converts GSA to aminolevulenic acid (ALA), 
which is the biosynthetic precursor to heme. Hu227 strains cells cannot synthesize ALA 
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naturally, so the cultures of this strain must be supplemented with ALA to produce and 
grow. Previously in our lab, 4-13C and 5-13C ALA were synthesized and included in 
growth media for Hu227 cells instead of regular ALA. The predicted pattern for ALA 
using the 13C labeled in positions 4 and 5 is shown below in Figure I.3. The asterisk 
represents the 13C labeled carbons.  
H2N OH
H2N O
OO
OO
4-13C - ALA 5-13C-ALA
* * H
 
 
                                                            
Figure I.3. Expected labeling patterns of 4 and 5-13C-ALA  
 Initial attempts to express heme containing proteins using this recombinant 
system focused on an enzyme from a related class of heme proteins. Dehaloperoxidase 
(DHP) is an enzyme found in a marine worm, Amphitrite ornate. DHP is a globular 
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heme-containing enzyme that provides the marine worm with the ability to catalyze the 
oxidative dehalogenation of halogenated phenols12.  Studies using UV-Visible absorption 
have demonstrated that exogenous ligand-ferric DHP is hexa-coordinated with water and 
has a proximal neutral histidine as axial ligand. It was proposed that this state activates 
the peroxide through an electron push-effect mechanism12. By synthesizing deuterium 
labeled ALA, incorporation of 2H into the heme of dehaloperoxidase via the biosynthetic 
pathway of the heme cofactor may be accomplished. This will open up the door for 
production of P450 enzymes to be used in biochemical studies involving P450 deuterium 
isotope effects aimed at understanding the deformylation of aldehydes. 
 In E.coli the biosynthesis of heme starts with the condensation of one glycine and 
one succinyl-CoA to form δ-aminolevulinic acid (ALA). Next is the condensation of two 
ALA molecules, catalyzed by ALA dehydratase enzyme, also called Porphobilinogen 
Synthase which forms porphobilinogen (PBG), as shown in Figure I.413. The four PBG 
molecules are then condensed by PBG deaminase (by elimination of the amino group) to 
form a 1-hydroxymethylbilane (HMB). This is then converted to uroporphrinogen III 
(Uro’gen) by uroporphyrinogen III synthase. The conversion from Uro’gen to 
protoporphyrin IX happens in several steps. First, the four acetyl side chains on Uro’gen  
are decarboxylated by Uro’gen decarboxylase which converts them to methyl groups and 
yields coproporphyrinogen III (Copro’gen). Two of the four propionyl groups undergo 
oxidative decarboxylation converting them to vinyl groups by Copro’gen oxidase which 
yields protoporphyrinogen IX. In the next step there is an oxidation of 
protoporphyrinogen IX, which adds more double bonds by removing six hydrogen atoms 
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to give protoporphyrin IX catalyzed by protoporphyrinogen oxidase. In the next step, 
Fe2+ is inserted to protoporphyrin IX by ferrochelatase.  
 
Figure I.4. Biosynthetic pathway of heme14.  The highlighted atom represents 13C 
I.C. Active site of CYP450BM3 and transient intermediates 
 As mentioned before, CYP450 is a class of monoxygenase enzyme, and studies 
relevant to these particular enzymes have been designed to gain a better mechanistic 
understanding of this human drug metabolizing systems. CYP450BM3 isoform is a fatty 
acid hydroxylase that uses NADPH and one molecule of molecular oxygen which 
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oxidizes long chain fatty acids. It is a member of the class II P450s, making it an 
important model for the human drug metabolism of P450’s. The BM3 enzyme is a single 
polypeptide, has a deep nonpolar pocket leading to heme center. The x-ray crystal 
structure of BM3 active site shows that there is a phenylalanine residue at position 87 and 
that iron at the heme center is bound to protein by a cysteine-thiolate linkage. Removing 
this Phe-87 from the active site and replacing it with any other amino acid with a smaller 
nonpolar side chain enhances the BM3 enzyme in the oxidation of aromatic substrates9. 
Li and colleagues replaced the Phe-87 with alanine and glycine and noticed that the 
hydroxylation of p-nitrophenoxydodeconoic acid (12-pNCA) was markedly increased.   
 Prior studies have shown that P450BM3 with a F87G mutant modification of the 
heme using aromatic aldehydes results in altered catalytic activity rather than inactivation 
of the enzymes10. Raner et al. also performed a similar study using stopped-flow 
experiment to determine different intermediates in the heme reaction involving CYPBM3 
F87G with 3-phenylpropianaldehyde (3-PPA) or 3-phenylbutyraldehyde (3-PBA) as 
substrates8. This study showed that the aldehydes lost the carbonyl carbon and the heme 
cofactor was alkylated at the γ meso position, in the course of this reaction as shown in 
Figure I.5.  
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Figure I.5. Proposed isoporphyrin intermediate in the reaction of 3-PBA8  
 One of the long term goals for this project was to develop technology that would 
be useful in the identification of transient intermediates in the peroxo-pathway for 
P450BM3-F87G. The hypothesis is that in the presence of hydrogen peroxide and an 
aldehyde substrate, P450BM3-F87G will form a transient peroxy-hemiacetal intermediate, 
which decomposes to form an isoporphyrin intermediate. Heme alkylation occurs in this 
reaction which proceeds with the formation of γ-meso isoporphyrin intermediate that 
must decay with the deprotonation at the γ-meso carbon. This deprotonation should show 
a fully expressed deuterium isotope effect in the stopped-flow experiment. To address 
this issue, deuterium (2H) labeled aminolevulinic acid (ALA) was synthesized for the 
incorporation of deuterium into the meso heme positions. Experiments described in this 
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thesis were designed to evaluate the ability of E.Coli to utilize ALA, synthesized with 2H-
labeles to produce a deuterated heme cofactor in order to probe.  
I.D. NMR studies of isotopically labeled heme 
Isotopic labeling with 13C or 15N may also be useful for NMR studies. The 
spectroscopic properties of any heme-protein usually result from the heme cofactor, 
which are related in turn to the electronic state of the central iron and the porphyrin itself. 
A low spin state exists, for example, when water is coordinated to the central iron in the 
axial position. A high spin state occurs when this water is removed, leaving iron existing 
as a pentacoordinated species1. These two spin states have distinct spectral patterns which 
allow the use of visible absorption spectrophotometry to monitor changes. Different 
forms of spectroscopy are also useful, along with UV/Vis, to probe minor changes in 
axial ligation and/or oxidation states of the heme group.    
 
10 
 
 
 
Figure I.6. Left: Typical porphyrin core 13C chemical shifts. (a) FeIII-porphyrinates with 
the S = ½, dπ electron configuration, (b) Fe
III-porphyrinates with the S = ½, (dxy)1 
electron configuration, and (c) FeIII-porphyrinates with the S = ³/², (dxy)
2(dxz,dyz)2(dz
2)1 
electron configuration. Right: Schematic representation of the 3a2u(π) and 3e(π) 
porphyrin orbitals. Relative sizes of the circles at each atom are proportional to the 
calculated electron density5. 
 
 Caignan and his collegues conducted a study with hydroxide complex of 
Pseudomonas aeruginosa heme oxygenase (HO) containing 13C labled heme, in which an 
OH served as a model for the OOH ligand of the FeIII-OOH intermediate. In this study, 
they conclude that 13C NMR chemical shifts can be used to determine the heme electronic 
structure5. As shown in Figure I.6.(a), the Cβ has the furthest downfield shift, indicating 
that the major electron density is located on Cβ in S = ½, dπ electron configuration have 
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spin delocalization into porphyrin 3e(π) orbital. Due to a very small shift, Cα has a small 
amount of unpaired density and Cm has no unpaired density. Ferrihemes with S = ½, 
(dxy)
1 electron configuration, on the other hand, have majority of their spin delocalization 
in the porphyrin 3a2u(π) orbital, suggesting in Figure I.6(b), that most of the electron 
density is located on the Cm due to the substantial downfield shift. Ferriheme with S = ³/², 
(dxy)2(dxz,dyz)2(dz
2)1 electron configuration has a significant amount of electron density 
on Cβ and Cα as indicated by the downfield shift, and Cm has no electron density.  
Since there are many questions concerning the electronic structure of heme in 
P450, conducting studies that will probe spin distribution using 13C-NMR paramagnetic 
spectroscopy will be useful in future applications. In particular, 13C-labeling of heme 
cofactor will provide a method of exploring the electronic spin density across the 
porphyrin backbone. One of the drawbacks is that using 1H-NMR is not helpful when 
probing paramagnetic hemoproteins and spin states. Previously, our lab successfully 
synthesized 13C-labeled aminolevulinic acid (ALA), a heme precursor, at positions 4 and 
5 and 15N has also been incorporated at the pyrrole nitrogens. E.Coli Hu227 bacterial cell 
line was used due to the inability of these cells to produce ALA. Using mass 
spectrometery, it was demonstrated that the mass of 13C-labeled heme increased by 8 
mass units and 15N-labeled heme increased by 4 mass units, as predicted based on the 
known biosynthetic pathway in E.Coli. However, the 13C MS data was slightly 
ambiguous. In the current study, the goal was to use ESI-MS to clearly show 13C 
incorporation in the heme. This technology will allow for the evaluation of electronic 
distribution within the heme cofactor of P450 enzymes using 13C paramagnetic NMR. 
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I.E. Synthesis of deuterium labeled aminolevulinic acid 
 For synthesizing deuterium-labeled aminolevulinic acid (2H-ALA), the procedure 
of Wang and Scott6 was chosen with slight modification. The reaction scheme of the 
synthesis is shown in Figure I.7A. The synthesis of 2H-ALA starts with labeled glycine 
and is protected by phthalic anhydride to yield phthalylglycine. Phthalylglycine is then 
treated with thionyl chloride to yield phthalimidoacetyl chloride. The next step requires 
that the phthalimidoacetyl chloride be coupled with zinc homoenolate. A palladium 
catalyst is used in order to form phthalimolevulic acid ethyl ester. But to get to the last 
step, the zinc homoenolate had to be synthesized by reacting [(1-ethoxycyclopropyl)-
oxy]trimethylsilane with zinc chloride in dry ether, which can be seen in Figure I.7B The 
zinc homoenolate then reacts with phthalimidoacetyl chloride to yield phthalimolevulic 
acid ethyl ester. In the next step, acid hydrolysis of phthalimolevulic acid ethyl ester with 
hydrochloric acid yields labeled aminolevulinic acid (ALA). For the pupose of this 
project, 2,2-D2 Glycine was used as the starting material to ultimately generate 
2H labeled 
ALA. 
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Figure I.7A: Synthetic procedure for the generation of ALA6  
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Figure I.7B: Synthesis of zinc homoenolate6   
 
CHAPTER II 
EXPERIMENTAL 
II.A. Preparation of Luria - Bertani broth (LB) media, CaCl2 solution and LB-Agar plates 
 The LB media was prepared by adding 4 g of LB powder mixture to a total 
volume of 200 mL of dH2O. A 80mM CaCl2 solution was prepared by adding 1.18 g of 
Calcium Chloride to 100mL of dH2O. LB-Agar solution for the plates was prepared by 
adding 3.75 g of agar and 5 g of LB powder to 250 mL of dH2O, and a magnetic stir bar. 
All 3 solutions were sterilized for 15 min and allowed to cool at room temperature. Once 
the solutions were sterilized, the LB-Agar solution was stirred room temperature on a stir 
plate, and when it was cool enough to touch, 100 mg/L of ampicillin and 10 mg/mL of 
ALA was added. Only 10 mg/mL of ALA was added to the LB media, with no 
ampicillin.  After that, the LB-Agar solution was poured in to the agar plates and once it 
solidified, it was then placed in a 20°C refrigerator. The preparation of the media and the 
sterilization of the media were done to grow non-virulent strain of E.Coli cell, Hu227. 
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II.B. Growing Hu227 untransformed cells in LB media 
Sterile techniques were employed through the whole procedure when growing 
Hu227 cells.  Using a 25-mL pipette, a 25 mL aliquot of LB/ALA media was transferred 
to a 50 mL Falcon tube. The media was then inoculated with the untransformed Hu227 
cells and they were than shaken at 200 rpms at 37° C overnight. The following day, the 
media was thick with growth. 
II.C. Procedure for making competent Hu227 cells 
E.Coli Hu227 cells were made competent with sterile techniques throughout the 
preparative steps. 10 mL of the Hu227 thick media was then transferred to another 50 mL 
falcon tube, along with 15mL of plain LB media. It was grown again for 30 min at 200 
rpm, 37°C. The cell cultures were transferred over to 6 of the 1.5 mL microcentrifuge 
tubes and were centrifuged for 1 min at 10,000 rpm. The supernatant was discarded and 1 
mL of ice-cold sterile 80 mMCaCl2 was added to the pellet and the cells were then 
suspended, very gently. Using chilled CaCl2 increases the permeability of the membranes 
of the cells. The suspended pellets were centrifuged again for 1 min at 10,000 rpm. The 
supernatant was discarded and the pellets were suspended in chilled CaCl2 solution and 
placed on ice for 10 min. The tubes were centrifuged again for a min at 10,000 rpm and 
resuspended in 200 µL of chilled CaCl2 and placed in -70°C for at least 3 hours before 
taking it out for transformation. Using the protocol for Plasmid DNA Purification, the 
QIAprep Spin Miniprep kit and a Microcentrifuge, both 102A2/BL-21 and 
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BM3F87G/HB101 were purified from overnight cultures of the respective cell lines 
grown in the presence of appropriate antibiotic to ensure plasmid maintenance.  
Another alternative method from Kotchoni et. al. was also used to make Hu227 
cells competent15, since p102A2 was not expressing well with Hu227 competent cells 
from the method above. For this experiment three seperate solutions had to be made in 
advance. Solution I (50mM Glucose, 25mM Tris-HCl – pH 8.0, 10mM EDTA – pH 8.0) 
was prepared by adding 4.5g of glucose, 1.5g of Tris, and 1.9g of EDTA to a 500 mL 
deionized water. The pH of the solution was taken down to 8.0 with HCl and than 
autoclaved. 4µg/mL lysozyme was also prepared in order to add into the solution I just 
before use. Solution II (0.2M NaOH, 1% (w/v) SDS) was prepared by first making a 
stock solution of 2M NaOH and a stock solution of 10% (w/v) SDS. The solution was 
than prepared just before use by diluting to 0.2M NaOH and 1% (w/v) SDS and was 
autoclaved. Solution III (8M Ammonium Acetate) was prepared by adding 61.6 g of 
ammonium acetate to 100mL of deionized water and was also autoclaved.  
An overnight culture was setup with 2mL of 102A2/BL-21and pT7po1 in a 
2.5mL eppendorf tubes. The cells were centrifuged at 5000 g for 5 min at room 
temperature. The pellets were then suspended in 200µL of Solution I, which contained 
the freshly added lysozyme. The solution was incubated for 5 min in room temperature. 
After 5 min of incubation, 400µL of freshly prepared Solution II was added and inverted 
gently 6 times. Immediately, 200µL of Solution III was added and mixed gently. It was 
then incubated on ice for 5 min and a white precipitate had formed. This was centrifuged 
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for 5 min at 10000 g and the supernatant was transferred to a new tube. To that 
supernatant, 600µL of isoproponal was added and mixed gently and kept at room 
temperature for 10 min. It was then centrifuged again for 5 min at 10000 g, but this time 
the supernatant was discarded and the pellet was washed with 400µL of 70% (v/v) 
ethanol. It was again centrifuged at 10000 g for 3 min, after which the supernatant was 
discarded and the pellet was left to air dry for 30 min to get rid of the residual ethanol. 
The pellet was resuspended in 30µL of 10mM Tris-HCl (pH 8.0) and was stored in -70°C 
freezer. 
II.D. Plasmid purification of 102A2 from BL-21; BM3F87G from HB101 
Plasmid DNA Purification using the QIAprep Spin Miniprep kit and a 
Microcentrifuge was used to purify both 102A2/BL-21 and BM3F87G/HB101. 102A2 in 
BL-21 and BM3F87G in HB101 cells were centrifuged at 10000 rpms for 5 min in 1.5mL 
centrifuge tubes. The supernatant was discarded and the procedure was repeated two 
more times. After the third time, the pelleted bacterial cell was resupended in 250 µL of 
Buffer P1 and transferred it to a microcentrifuge tube provided by the kit. Also added 250 
µL of Buffer P2 and inverted the tube 6 times, and 350 µL of Buffer N3 and also inverted 
the tube 6 times. Once everything was mixed properly, the solution was centrifuged for 
10 min at 13,000 rpms. The supernatant from last step was transferred to QIAprep spin 
column by decanting. It was then centrifuged for a minute to discard the flow-through. It 
was then washed further to remove trace nuclease activity by adding 500 µL of Buffer PB 
and centrifuging for a minute. The solution was again washed by adding 750 µL of 
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Buffer PE and centrifuged another minute. After discarding the flow-through, the 
solution was centrifuged for an additional minute to remove the residual wash buffer, so 
the residual ethanol will not inhibit subsequent enzymatic reactions. The spin column was 
then transferred to a clean 1.5 mL microcentrifuge tube, to elute DNA by adding 50 µL 
of Buffer EB. After letting the solution stand for a minute, it was then centrifuged for an 
additional minute, and the purified 102A2 and BM3F87G plasmid was stored in -70°C 
freezer. 
II.E. Procedure for transformation of Hu227 cells with p102A2, and pBM3F87G 
plasmids 
 Both Hu227 competent cells and plasmids 102A2 and BM3F87G were thawed 
out on ice, and 200 µL of the competent Hu227 cells were transferred over to two of the 
sterile 1.5 ml microcentrifuge tubes. Purified 102A2 plasmid (25µL) or BM3F87G 
plasmid (25µL) was added to the 200 µL of Hu227 cells in separate tubes.  The tubes 
were flicked rapidly by hand several times to increase the efficiency. The tubes were then 
incubated on ice for 30 min. After the incubation on ice, the solutions were transferred 
over to a hot water bath with temperature of 42°C for 50 seconds. This was done in order 
to heat shock the cells to increase the pores in the cells so it will be easier for the 
plasmids to enter the cells. After the heat shock, the solutions were again placed on ice 
for 2 minutes. After the incubation on ice, 900 µL of LB/ALA/Amp was added to the 
mixture and incubated for an hour at 37°C shaking at 200 rpms. After an hour, 100 µL of 
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each growth mixture was streaked onto the already made LB/ALA/Amp plates. The 
plates were then allowed to incubate overnight at 37°C.  
II.F. Preparing and sterilization of Terrific Broth (TB) media and expression and 
harvesting of BM3F87G cells 
The TB media was prepared by mixing 47.6 g of TB powder to 1L of dH2O, in a 
wide-mouth culture flask. The six flasks were then placed in an autoclave for 
sterilization. Once the media was cool enough, 100 mg/L of ampicillin and 10 mg/L of 
ALA was added to the media. After that, a single colony of BM3F87G/Hu227 cell was 
used to inoculate all the cultures. The cultures were mixed in a gyroshaker at room 
temperature with a shaking rate of 200 rpms. After 40 hours of agitation of the cultures, 
the cells were induced with 150 mg/L of IPTG, for expression of the recombinant P450 
and the speed was reduced to 70 rpms and left overnight. The cells were then harvested 
by centrifuging the cells at 10,000 rpms for 10 min in the Beckman-Coulter centrifuge. 
The supernatant was then discarded and the pellets were then suspended in 25 mL of 50 
mM phosphate buffer (pH 7.4) and 15% glycerol. The solution was homogenized using a 
glass homogenizer and 10 mg of lysozyme was added to the solution for cell lysis. It was 
stirred for an hour at room temperature and the cell membranes were then broken by 
using a sonicator. The solution was centrifuged at 18,000 rpm for 45 minutes, and the 
supernatant stored in -70°C freezer. 
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II.G. Synthesis of deuterated aminolevulinic acid (2H- ALA) 
 Glycine-2,2-D2 was purchased from Cambridge Isotope Laboratories, Inc. 
dALA 
was prepared by the procedure Wang and Scott described in their paper6. The scheme 
used for this synthesis of ALA was presented in the Background, Figure I.7 (A) and 
Figure 1.7 (B). A more detailed procedure for the synthesis of ALA is now presented. 
Most of the reactions used were very sensitive to moisture, hence they were carried out 
under an atmosphere of argon gas.  
Glycine (1.0005g) was combined with phthalic anhydride (2.0087g) in a 50 mL 
round bottom flask. Indirect heat was used to fuse the solids using a Bunsen burner. 
Heating the solids for approximately 3 minutes caused the white powders to liquefy. 
Soon after, solid crystals began forming on the inside of the flasks. The product was then 
recrystallized from water and stored in the refrigerator. After 30 minutes, it was filtered 
and the yield of the resulting product, phthalylglycine was 2.2548 g, 74.9% yield. It was 
then stored in a desicator at room temperature.  
Dried phthalylglycine (2.2541 g) and 12 mL of thionyl chloride was refluxed 
overnight in a 25 mL round bottom flask. The reaction was carried out under continuous 
argon gas flow in a 80°C oil bath. The liquid was then cooled and the thionyl chloride 
was removed with a rotorvapor hooked to a vacuum. The resulting yellow powder was 
analyzed by NMR and found to be the desired product phthalimidoacetyl chloride. The 
overall yield of this product was 2.0632 g, 91.5% yield 
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In the subsequent step, zinc chloride (2.01g) was fused in a 100 mL round bottom 
flask with indirect heat from Bunsen burner under vacuum, and cooled under vacuum to a 
white solid. Approximately 30 mL of diethyl ether was added and the zinc chloride was 
stirred at room temperature under argon gas flow. It was then refluxed at room 
temperature for 2 hours to obtain a homogenous mixture. After that, 6.0 mL of dry [(1-
ethoxycyclopropyl)-oxy]trimethylsilane was added into the reaction drop wise with a 
syringe. After 5 minutes of adding it slowly, the solution turned cloudy solution, and the 
stirring was continued at room temperature for 1 hour. That was then followed by 
additional reflux in a hot oil bath for 30 min to obtain the zinc homoenolate.  
This solution was stirred further in an ice bath under argon gas. To this solution 
Tetrakis (triphenylphosphine) palladium (155 mg) and phthalimidoacetyl chloride (2.0 g) 
was added. After waiting for 30 min to obtain a homogenous mixture, 3 mL of N, N-
dimethylacetamide was added via a syringe very slowly. The solution was stirred at 0°C 
for 1 hour and then stirred at room temperature for additional 2 hours under argon gas. 
The solution was then evaporated using a Rotorvap, under vacuum. The light brown 
residue was dissolved in 100 mL of dichloromethane and the solution was transferred to a 
250 mL separatory funnel and washed with 50 mL of water. The aqueous fraction was 
discarded and the dichloromethane fraction was again washed with 50 mL saturated NaCl 
– water. The organic fraction was saved and dried overnight under vacuum. The oily-
orange solution that resulted was dried again using a Rotorvap under vacuum in an 
attempt to attain the solid product, but each time, only an orange oil resulted. To obtain a 
solid product, recrystallization from ethanol was attempted but again, no crystals were 
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produced. The speed-vac was again used to remove the solvent and the oily material was 
again produced. An NMR spectra of the sample was taken, confirming the presence of 
the product.  
Phthalimidolevulinic acid ethyl ester (1.8134g) and 1:1 mix of hydrochloric acid: 
acetic acid solution was placed in a 50 mL round bottom flask to reflux for 6 hours at 
120°C. The deep yellow solution was evaporated using a Rotorvap under vacuum. To 
remove excess acid, the solution was washed with 20 mL of water. The solid was then 
taken up with 40 mL of water and transferred to a 125 mL seperatory funnel. To remove 
phthalic acid, the aqueous fraction was washed with 25 mL of ethyl acetate four times. 
The aqueous fraction was evaporated under vacuum to a brown-oily residue. To obtain 
solid product, recrystallization from ethanol and diethyl ether was attempted, but no 
crystals were produced. Recrystallization with acetone was also tried, but again no 
crystals were produced. Finally, drop by drop of cold diethyl ether was used and kept to 
freeze dry overnight to get 1.6613 g of white solid crystals. These were then stored at -
20°C in a glass vial. 
II.H. Growing Hu227/DHP using synthesized 2H -ALA 
Hu227 and DHP were grown according to what was described previously. The 
media contained LB/2H-ALA/Amp and the DHP harboring E. Coli was used to inoculate 
and cells were grown at 30°C at 200 rpms overnight. Once IPTG was added to induce 
protein expression, the solution was centrifuged for 10 min at 10,000 rpm. The pellets 
were then reconstituted with 50 mM, pH 7.4 phosphate buffer (PO4
3-). Then the cells 
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were lysed by adding 50 mg of Lysozyme and used a homogenizer to homogenize the 
solution. It was then stirred at room temperature for an hour and was sonicated at full 
speed for a minute, two times. The solution was again centrifuged for 45 min at 18,000 
rpm. 1:1 ratio of 15% glycerol was added to the 2H-DHP supernatant and stored in -80°C 
freezer. 
II.I. Extraction of heme from DHP for LC-MS data 
 Once 2H-DHP supernatant was thawed, 3 mL of the supernatant was transferred 
to a screw top test tube and 2M HCl (200 µL) was added to each of the test tube, and was 
incubated at room temperature for 30 min, after which 2 mL of ethyl acetate was added to 
one of the test tube, 2 mL of petroleum ether for 2nd of the 3 test tube, and 2 mL of 
Isobutanol was added to the last test tube. Even though, a clear organic and aqueous layer 
could be seen, they were all centrifuged for further clarity. Using a Pasteur pipette, the 
organic layer was drawn out and some of the sample was evaporated under vacuum for 2 
hours. The rest of the sample was saved for subsequent HPLC analysis and isolation. The 
reddish pellet obtained was reconstituted with 60:40 Acetonitrile: water (1% TFA) for 
both absorption spectra and HPLC chromatographic analysis. For LC-MS, the pellets 
were treated either with the mobile phase (50:50 ACN: H20, 1% TFA), or with Methanol.  
Since the LC-ESI results had a lot of impurities, the samples were processed by 
HPLC and the fractions were collected between 1-15 minutes. The organic layer that was 
saved in the above step was transferred to a HPLC glass sample vial. This was then 
placed in the autosampler rack of a Shimadzu HPLC system equipped with a C8 column. 
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The flow rate for the column was 1.0 mL/min and the absorbance of the eluent was 
observed at 398 nm. The mobile phase used was 60:40 mixture of ACN:H2O with 0.1% 
TFA. The largest peaks were collected at retention times from 4 – 9 minutes and the 
samples were evaporated under vacuum. The pellets were treated with methanol and the 
data were obtained from LCQ Advantage Thermo Finnigan ion trap mass spectrometer 
with electrospray ionization coupled to an Agilent HP1100 HPLC.  
II.J. Purification of 2H-DHP by anion exchange DEAE column 
The column was first washed with 20% EtOH and washed again with 20 mL of 
50 mM phosphate buffer (PO4
3- )(pH 7.4), and was loaded with the crude cell lysated, 
diluted 1:4 in 15% glycerol. The column was washed with 20 mL of 50 mM PO4
3- , 100 
mM PO4
3- , 150 mM PO4
3- , and 200 mM PO4
3- buffer to generate a stepwise elution 
gradient. The DHP protein, which adhered to the column during the 50 – 100mM 
phosphate wash was eluted out. For both 150 mM PO4
3- and also 200 mM PO4
3- elution, 
visible absorption spectra was taken and samples were stored in -80°C. For the 
absorption spectrum, the sample was treated with CO gas and absorption between 400-
500 nm was recorded. After the background correction, a pinch of sodium dithionate was 
added for both the sample and background, and an absorption spectrum was then taken.  
This represents the reduced vs. reduced-CO difference spectrum for the enzyme.  
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II.K. Preparation of EPR samples 
 Previously in our lab, [4-13C] ALA DHP, [5-13C] ALA DHP, 15N-ALA DHP, and 
pure DHP were prepared. In order to run an EPR spectrum on these samples, the enzyme 
was oxidized to the ferric form using potassium ferricyanide to ensure a homogeneous 
sample. Once the samples were thawed, they were treated with potassium ferricyanide at 
which point the sample turned a reddish-yellow color. This sample was then passed 
through a G-25 Sephadex column to remove excess ferricyanide. The red fraction was 
extracted out and the yellow fraction (ferricyanide) was discarded. Once absorbance 
spectra were taken for all four samples, the concentration of all of them had to be 
normalized. After adjusting all of them to the same concentration, the samples were put 
in clear fused quartz EPR tube and frozen in liquid nitrogen by immersing slowly over a 
period of 15 to 20 seconds.  
II.L. Extraction of heme from DHP for MALDI data 
 The DHP, 13C-DHP and 2H-DHP supernatant from the sample (3 ml) was 
transferred to a screw top test tube and 1.5 mL of 1M HCl was added to each of the test 
tube, so the heme could be released into the solution. It was incubated at room 
temperature for an hour which produced a pinkish slurry solution. To this solution, 3 mL 
of methyl ethyl ketone was added and each of the tubes was centrifuged for 30 min at 
2500 rpm. After centrifugation, the organic layer was drawn out and the solution was 
made ready for MALDI analysis. The matrix used was 12 µL of α-cyano-4-
hydroxycinnamic acid (CHCA) in 50% acetonitrile with 0.1% trifluoroacetic acid (TFA). 
26 
 
 
27 
 
To spot the solution, 1µL of the DHP, 13C-DHP and 2H-DHP samples were added to  
12µL of the matrix diluent (50% acetonitrile with 0.1% TFA) and a 12µL aliquot of the 
matrix solution. From this sample, 0.5µL was spotted on a MALDI plate for analysis. 
The samples were analyzed in an Applied Biosystems 4700 Proteomics Analyzer and this 
analysis was conducted in reflector positive mode. 
 
CHAPTER III 
RESULTS AND DISCUSSION 
III.A. Synthesis of 2H-aminolevulinic acid (2H-ALA) 
 The first step of the synthesis was formation of phthalylglycine with the yield of 
75%. 2,2-D2 Glycine was reacted with phthalic anhydride to form 
2H-phthalylglycine. 
Nuclear magnetic resonance spectroscopy was used to characterize the products and was 
carried out on a JEOL JNM-ECA500 FT NMR system. Figure III.1 shows the synthesis 
of phthalylglycine from phthalic anhydride and glycine (2H denoted by D). Table III.1. 
shows the available literature values, the chemical shift assignments and 1H-NMR data 
for the synthesized 2H-Phthalylglycine. The literature values from Wang and Scott6 for 
the phthalylglycine (CH2COOH) was a doublet at 4.40 ppm. In the 
2H-phthalylglycine 
(C2H2COOH), there should not be any doublet peak, and there was not, if the deuterium 
had been incorporated since 1H-NMR can only detect protons, not deuterium. The 
assigned chemical shift of 2H-phthalylglycine at 7.90 ppm was close to the literature 
value of 7.82 ppm. The peak at 2.50 ppm is DMSO solvent peak.  
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Phthalic Anhydride 2H-Phthalylglycine  
Figure III.1. The synthesis of 2H-phthalylglycine from phthalic anhydride and 2,2-D2 
glycine.   
 
Table III.1. The available literature values, the chemical shift assignments and 1H-NMR 
data for the synthesized 2H-phthalylglycine. 
 
 Experimental (1H-
NMR, ppm) 
Literature6 Assignment 
 
2H-Phthalyglycine 
 
2.45 
No peak 
7.85 
 
 
4.40 
7.82 
 
DMSO (solvent) 
CH2COOH (lit) 
AA’BB’, 4H 
  
The next step in synthesis of ALA was the formation of phthalimidoacetyl 
chloride. To do this, the reactant phtalylglycine from the last step had to be completely 
dry. The dried phthylglycine was reacted with thionyl chloride to yield phthalimidoacetyl 
chloride. The excess thionyl chloride was evaporated off and the percent yield was 
calculated to be 92%. Figure III.2. shows the synthesis of 2H-Phthalimidoacetyl Chloride 
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from 2H-phthalylglycine and thionyl chloride. Table III.2 shows the 1H-NMR data of the 
synthesized 2H-phthalimidoacetyl chloride. Similar to the last step, there was no peak at 
4.80 ppm, indicating there was an incorporation of deuterium. In the literature, there was 
a doublet at 4.80 ppm (CH2COCl) and the peaks at 7.78 ppm from the literature were 
close to the experimental peak also at 7.78 ppm. A singlet peak at 7.24 ppm was 
indicative of a D-chloroform solvent peak.  
NCD2COOH
O
O
NCD2COCl
O
O
2H-Phthalylglycine 2H-Phthalimidoacetyl Chloride
SOCl2
 
Figure III.2. Synthesis of 2H-phthalimidoacetyl chloride from phthalylglycine and 
thionyl chloride. 
 
Table III.2. The available literature values, the chemical shift assignments and 1H-NMR 
data for the synthesized 2H-phthalimidoacetyl chloride. 
 Experimental (1H-
NMR, ppm) 
Literature6 Assignment 
 
2H-Phthalimidoacetyl 
Chloride 
 
 
No peak 
7.24 
7.78 
 
 
4.80 
 
7.78 
 
CH2COCl (lit) 
CDCl3 (solvent) 
AA’BB’, 4H 
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 The third step of this synthesis was the most labor intensive beacause zinc 
homoenolate solution had to be used in subsequent reaction with 2H-phthalimidoacetyl 
chloride. It is important to note that all the reagents had to be kept dry at all times and 
under an atmosphere of argon gas during the synthesis of zinc homoenolate. The overall 
yield for the synthesis of 2H-phthalimidolevulinic acid ethyl ester was 88%. Figure III.3. 
shows the synthesis of 2H-phthalimidolevulinic acid ethyl ester from 2H-
phthalimidoacetyl chloride and zinc homoenolate. Table III.3. shows the 1H-NMR data 
for 2H-phthalimidolevulinic acid ethyl ester. All the 1H-NMR data from 2H-
phthalimidolevulinic acid ethyl ester was in close agreement with the literature values6. 
Just like the last steps, the deuterium was still intact and incorporated which is shown by 
the absence of a peak at 4.56 ppm, which is consistent with the results from previous 
steps. All other protons were observed in the NMR spectra consistent with specific 2H 
incorporation. 
 
NCD2COCl
O
O
Zn(CH2CH2COOEt)2
Pd(PPh3)2Cl2
NCD2COCH2CH2COOEt
O
O
2H-Phthalimidoacetyl chloride
2H-Phthalimidolevulinic acid ethyl ester  
Figure III.3. Synthesis of 2H-phthalimidolevulinic acid ethyl ester from 2H-
phthalimidoacetyl chloride and zinc homoenolate. 
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Table III.3. The available literature values, the chemical shift assignments and 1H-NMR 
data for the synthesized 2H-phthalimidolevulinic acid ethyl ester. 
 Experimental (1H-
NMR, ppm) 
Literature6 Assignment 
 
2H-
Phthalimidolevulinic 
acid ethyl ester 
 
1.23 
2.60 
2.91 
4.19 
No peak 
7.24 
7.78 
 
 
1.26 
2.65 
2.84 
4.14 
4.56 
 
7.80 
 
t, 3H, CH2CH3 
m, 2H, COCH2CH2 
m, 2H, COCH2CH2 
q, 2H, OCH2CH3 
NCH2CO (lit) 
CDCl3 (solvent) 
AA’BB’, 4H 
 
 The last step of this synthesis was the acid hydrolysis and deprotection of  2H-
phthalimidolevulinic acid ethyl ester to yield 2H-Aminolevulinic acid (2H-ALA), the final 
product. Product yield for this step was calculated to be 92%. Figure III.4 shows the 
synthesis of 2H-aminolevulinic acid and Table III.4. shows 1H-NMR data of 2H-
aminolevulinic acid. The 1H-NMR peak at 4.10 ppm for the last step indicated that the 
protons had exchanged with deuterium.  The other two peaks were in agreement with the 
literature values, but where there should have been no peaks at 4.13 ppm if deuterium 
was incorporated; there was a doublet at 4.10 ppm which would indicate 2 protons at the 
5th position of ALA. The conclusion is that acid hydrolysis of 2H-phthalimidolevulinic 
acid ethyl ester converted the deuterium which was incorporated in the last step to 
exchange back with protons. Due to the conversion between deuterium and hydrogen 
during acid hydrolysis, another alternative method to make 2H-ALA was chosen. A 
detailed method to make 2H-ALA is described below in III.B. 
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NCD2COCH2CH2COOEt
O
O
6N,HCl
Cl-H3N
+CD2COCH2COOH
2H-Phthalimidolevulinic acid ethyl ester 2H-Aminolevulinic acid  
Figure III.4. The synthesis of 2H-ALA from acid hydrolysis of 2H-phthalimidolevulinic 
acid ethyl ester. 
 
Table III.4. The available literature values, the chemical shift assignments and 1H-NMR 
data for the synthesized 2H-aminolevulinic acid. 
 Experimental (1H-
NMR, ppm) 
Literature6 Assignment 
 
 
2H-ALA 
 
 
 
2.70 
3.95 
4.10 
 
2.71 
2.90 
4.13 
 
 
 
m, 2H, 13COCH2CH2 
m, 2H, 13COCH2CH2 
d, 2H, NCH2CO 
 
III.B. Alternative method to make deuterium-ALA (2H-ALA) 
 Since in the previous method, the deuterium exchanged with hydrogen, it was 
necessary to come up with a new method to make 2H-ALA. The last step of the reaction 
in the synthesis of ALA from Wang and Scott6 was the acid hydrolysis and deprotection 
of the phthalimidolevulinic acid ethyl ester. It is probably due to the presence of acid and 
water that deuterium exchanged with hydrogen. From this logic it was possible to 
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synthesize 2H-ALA by adding deuterium oxide and 2M HCl to pure ALA. For both 
regular ALA and for 2H-ALA, 1H-NMR spectra was taken with the same concentration in 
each of the tubes. Figure III.5 and III.6 shows 1H-NMR spectra of regular ALA and 2H-
ALA respectively.  
 
 
Figure III.5. 1H-NMR spectra of regular ALA. 
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Figure III.6. 1H-NMR spectra of synthesized 2H-ALA.    
OHH2N
O
O
Aminolevulinic Acid
OHH2N
O
OD
D
D
D
D
D
2H-Aminolevulinic Acid
H
H
H
H
H
H
2.55
2.753.95
 
Figure III.7. Diagram of regular ALA and deuterium-labeled ALA. 
In Figure III.5, regular ALA was prepared with solvent deuterium oxide (D2O). 
Once 1H-NMR spectra was taken, 25 µL aliquots of 2 M HCl was added to the NMR 
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tube and each time 1H-NMR spectra was taken. When 150 µL of 2 M HCl, had been 
added, the peaks at 2.55 pppm, 2.75 ppm and at 3.95 ppm disappeared.  Looking at 1H-
NMR spectra of regular ALA, the triplet at 2.55 ppm and 2.75 ppm and the singlet at 3.95 
ppm is considerably reduced in the 1H-NMR spectra of 2H-ALA. Looking at Figure III.6, 
the peaks at 2.55 ppm, 2.75 ppm and at 3.95 ppm has very little intensity compared to 
Figure III.5. Since 1H-NMR can only detect protons and cannot detect deuterium, the 
absence of the proton peaks in Figure III.6. clearly indicated the incorporation of 
nd rd th position of ALA. deuterium into the 2 , 3  and the 5
III.C. Plasmid purification results 
 One of the goals of this project was to generate enough production of P450 BM3 
since this plasmid contained T7 promoter for control of expression, so this recombinant 
plasmid can be used in 2H – heme incorporation. Since E.Coli Hu227 cells do not contain 
the gene for expressing T7 polymerase, these plasmids cannot be expressed in Hu227 
cells. In order to express in Hu227 cells, it is important to transfect the cells with a DNA 
that will allow T7 polymerase expression. A two step transformation with plasmid T7 
polymerase 1 (pT7po1) was attempted. This involved imparting the Hu227 cells with 
kanamycin resistance and transforming the second plasmid BM3. The QIAGEN kit 
method to make competent cells was not as successful, so an alternative method from 
Kotchoni et al15 was successfully used to make better competent cells. Figure III.8 shows 
Agarose Gel Electrophoresis of pT7po1 comparing the QIAGEN kit and the method from 
Kotchoni et al. It was observed that the competent cells using the method from Kotchoni 
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produced a band with much greater intensity indicating a much higher yield of plasmid, 
which can be seen on lane 1. The competent cells made using the method from QIAGEN 
can be seen on lane 2. The problem was that once both plasmids were transformed into 
Hu227 cells, the expressions of the cells were very low after the induction with IPTG. It 
appears therefore that the expression system in Hu227 is not effective. Figure III.9 shows 
the gel in which all the plasmids were purified and transformed. In lane 1 is p102A2, lane 
2 is pBM3F87G, lane 3 is pBM3W8G7 and lane 4 is pBMH. All the plasmids were then 
expressed in Hu227 cells and induced with IPTG. The BM3F87G in Hu227 was the only 
one to express fairly well compare to 102A2/Hu227, BM3W87G/Hu227 and BMH/Hu227. 
It correlated to the fact that pBM3F87G had the brightest band as seen in Figure III.9. Once 
BM3F87G/Hu227 was transformed and expressed, an absorbance spectrum of CO-reduced 
heme complex of BM3F87G was taken as shown in Figure III.10. Looking at the 
absorbance spectra, it can be seen that the peak is right at 450 nm is typical of the 
absorbance associated with P450 enzymes. This makes it easier to track the expression of 
P450 enzymes in whole cells, and is therefore useful in determining whether to harvest 
the cells based on their expression. The yield of BM3F87G is close to 100 nmoles of 
this particular enzyme in P450’s.  
 
BM3/1L, which is typical expression of 
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 Figure III.8. Agarose gel electrophoresis comparing two different methods to make pT7 
 
 
 
Figure III.9. Agarose gel electrophoresis of plasmid controls 
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Figure III.10. Absorbance spectrum of CO-reduced P450 BM3F87G in whole cells. 
  
III.D. Dehaloperoxidase expression levels and purification 
 Dehaloperoxidase (DHP) enzyme was chosen for the 2H incorporation of heme 
protein, as discussed previously. Aminolevulinic acid (ALA) was required for the cells in 
order to express since they cannot generate ALA on their own. Therefore, incorporating 
deuterium labeled ALA (2H-ALA) into the cells ensured the incorporation of deuterium 
into the heme of DHP. DHP was expressed and purified successfully from E.Coli Hu227 
cells. These cells were grown in Luria Bertani (LB) growth media containing 2H-ALA. 
Figure III.11 displays an absorbance spectrum of CO-reduced heme complex of purified 
DHP. The λmax of purified DHP is right at 420 nm, typical DHP peak, with absorption of 
P450 peak 
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about 0.050 in cultures, which displayed good expression. Even the 13C-labeled 
dehaloperoxidase and 2H-labeled deahloperoxidase showed decent expression levels. 
Figure III.12 and Figure III.13 shows an absorbance spectrum of CO-reduced heme 
complex of [5-13C] DHP and 2H-DHP respectively. The λmax of both purified [5-
13C] DHP 
and 2H-DHP is also right at 420 nm with absorption of about 0.020 in cultures. 
 
λmax  = 420 
nm 
Figure III.11. Absorption difference spectrum of CO-reduced heme complex of purified 
DHP in whole cells 
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420 nm 
Figure III.12 Absorption difference spectrum of CO-reduced heme complex of purified 
[5-13C] DHP in whole cells 
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420 nm 
Figure III.13. Absorption difference spectrum of CO-reduced heme complex of purified 
2H-DHP in whole cells 
 
III.E. Electron paramagnetic resonance (EPR) spectroscopy 
 EPR spectroscopy was carried out using a Bruker Instruments EMX EPR 
spectrometer, equipped with an Oxford Instruments ESR 900 liquid helium cryostat. 
Currently the EPR results for 15N-DHP, [4-13C] DHP, [5-13C] DHP and pure DHP are 
inconclusive. The goal of this study is to develop technology that would be useful in the 
identification of transient intermediates in the peroxo-pathway. If there is incorporation 
of 13C or 15N in the heme of DHP, the peaks may show broadening or splitting if coupling 
to these isotopes is significant. During the preparation of the DHP samples for EPR, the 
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absorbance spectrum was taken in order to get all of them to the same concentration. 
Figure III.14 shows the absorbtion spectra of all four samples after column purification. 
Once the concentrations were determined and normalized to the unlabeled sample, the 
samples were put in a clear fused quartz EPR tubes and frozen in liquid nitrogen over a 
period of 15 to 20 seconds. 
 
 
Figure III.14 Absorption spectrum of 15N -DHP, [4-13C] DHP, [5-13C] DHP and pure 
DHP in preparation for EPR analysis. 
 
Several EPR spectra with varying concentration of isotopically-labeled and 
unlabeled DHP were recorded and analyzed. The concentration of 15N-DHP, [4-13C] 
DHP, [5-13C] DHP was approximately 200 µM but the concentration of unlabeled pure 
DHP was approximately 70 µM. The samples were examined at X-band frequency, 
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shown in Figure III.15 and Figure III.16. Figure III.15 shows the EPR spectra for DHP 
samples at g = 2 region. The spectra looks the same for all the samples, but there is a 
small signal around g = 2.056 for [5-13C] DHP. This could be more likely a disrupted iron 
species or it could be due to the isotopic effect from [5-13C] DHP as opposed to [4-13C] 
DHP, or it could potentially also be a contamination from an impurity in the sample. 
Also, in Figure III.16, at g = 6 region, [5-13C] DHP also shows a little bit of broadening. 
Though it is not clear whether this is significant, more studies in the future might be 
worth undertaking.  
 
 
Figure III. 15. EPR spectra of DHP samples at X-band in the g=2 region using 0.5 mW 
microwave power, a field sweep from 500 to 4000 G modulation amplitude of 15G, and 
temperature of 10K. 
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Figure III. 16. EPR spectra of DHP samples at X-band in g=6 region using 0.5mW 
microwave power, a field sweep from 500-1600 G modulation amplitude of 15G, and 
temperature of 10K. 
 
III.F. LC-MS analysis of isotopically labeled heme from dehaloperoxidase 
 High performance liquid chromatography – mass spectrometry with electrospray 
ionization (LC-MS) was conducted on heme that had been extracted and purified from 
dehaloperoxidase. Since the MS results had a lot of contaminations and impurities, the 
samples were further purified using HPLC and the heme fraction at 4.43 min was 
collected as shown in Figure III.17. The solvent from this fraction was evaporated and 
resuspended in the mobile phase and subsequently subjected to analysis using LC-MS.  
The LC-MS chromatograms for unlabeled heme from DHP using unlabeled ALA, 13C 
heme from DHP using [5-13C] ALA and 2H heme from DHP using 2H-ALA are shown in 
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Figure III.18.  As expected, the blank had no detectable ion at m/Z of 616, but DHP, 13C-
DHP and 2H-DHP all had a 616 m/Z. The fact that 13C-DHP had ion at 616 m/Z, not 624 
m/Z, as shown in Figure III.19, suggested that eight 13C atoms were not successfully 
incorporated into the heme. Also the fact that 2H-DHP had a 616 m/Z indicated that 
deuterium had not fully exchanged with hydrogen. To further clarify the data, 
esterification of the heme was also done by adding 5% sulfuric acid to methanol. This 
was done by locking the two free carboxylic acid group to a methyl group so the charge 
on heme will be +3. The analysis of LC-MS data for the esterification of heme showed 
that, esterification did not work due to the fact that there was still 616 m/Z on unlabeled 
DHP instead of expected 205 m/Z (616 mass: 3 charge). Previously, it was shown that 
13C-ALA was incorporated into DHP and a clear 624 m/Z peak was shown. But, since 
there was no 624 m/Z peak in the current sample of DHP but a 616 m/Z was observed, 
another ionization method, MALDI was used in order to clarify the 616 m/Z of 13C-DHP. 
As expected, there was a clear 624 m/Z peak, but also a 616 m/Z peak on MALDI. A 
possible reason for this could be that the cell cultures of DHP/Hu227 were contaminated. 
If there was no contamination, there should have only been a clear 624 m/Z peak, but 
because there was a higher ion peak at 616 m/Z and not 624 m/Z was probably due to 
contamination, as shown in Figure III.20.  Re-plating DHP/Hu227 on a LB/ALA/Amp 
plate and growing fresh cultures out of that eliminated the possibility of contaminants. 
The absence of 624 m/Z peak of 13C-DHP on LC-MS (ESI) and presence of 624 m/Z by 
MALDI is probably a dilution issue because LC-ESI the samples molecule have to travel 
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through the mobile phase before they are ionized in which they are already diluted. In 
MALDI there is no mobile phase it has to travel through.  
 
Heme 
fraction 
collected at 
4.43 min 
Figure III.17. HPLC purified heme from dehaloperoxidase observed at 398 nm. 
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Figure III.18. LC-MS selective ion chromatogram (615.5 - 616.5) of purified 
isotopically labeled heme from DHP for blank, DHP expressed in unlabeled ALA, 13C-
DHP overexpressed in [5-13C] ALA and 2H-DHP overexpressed in 2H-ALA. 
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Figure III.19. LC-MS selective ion chromatogram (623.5 - 624.5) of purified 
isotopically labeled heme from DHP for blank, DHP expressed in unlabeled ALA, 13C-
DHP overexpressed in [5-13C] ALA and 2H-DHP overexpressed in 2H-ALA. 
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Figure III.20. MALDI-TOF spectrum of 13C labeled heme from DHP, displaying a 
major peak at 616 m/z and a minor peak at 624 m/z. 
 
 
III.G. MALDI-TOF analysis of isotopically labeled heme from dehaloperoxidase 
 Matrix Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry 
(MALDI-TOF) was used for analysis of heme from DHP because it proved to be a better 
ionization technique, as discussed previously in III.F. Unlabeled heme from DHP using 
unlabeled ALA, 13C heme from DHP using [5-13C] ALA and 2H heme from DHP using 
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2H-ALA were analyzed by MALDI to test for successful incorporation of isotopically 
labeled atoms in to the heme. The spectral data of this analysis is shown in Figure III.19, 
Figure III.20 and Figure III.21 respectively.  When comparing the MALDI-TOF 
spectrum of unlabeled heme sample (Figure III. 19) to the 13C-labeled heme sample 
(Figre III. 20), there is an increase in mass from 616 m/z to 624 m/z which suggests that 
eight 13C atoms were incorporated into the heme as expected. However, when comparing 
the MALDI-TOF spectrum of unlabeled heme sample (Figure III.19) to the 2H-labeled 
heme sample (Figure III.21), there is no increase in mass 616 m/z to 624 m/z, which 
clearly indicates there was no incorporation 2H-labeled atoms in the heme. These data 
concludes that the deuterium was not incorporated into the heme of DHP. The reason for 
this could be due to the hydrogen in water environment replacing deuterium in heme. 
Another reason that deuterium could not be incorporated could also be because of a slow 
exchange of deuterium and hydrogen during enzymatic reaction of ALA to heme as 
shown in the biosynthetic pathway of heme in Figure I.4.  
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Figure III.21. MALDI-TOF spectrum of unlabeled heme from DHP, displaying a major 
peak at 616 m/Z. 
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Figure III.22. MALDI-TOF spectrum of 13C labeled heme from DHP, displaying a  
major peak at 624 m/Z. 
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Figure III.23. MALDI-TOF spectrum of 2H labeled heme from DHP, displaying a major 
peak at 616 m/Z. 
 
 
 
 
 
 
 
CHAPTER IV 
CONCLUSIONS 
 Paramagnetic NMR can be a powerful tool for probing electronic distribution and 
spin-densities within the heme macrocycle. A significant limitation to its use in 
cytochrome P450 studies is that natural abundance of 13C is relatively low, and P450 
enzymes have proven resistant to heme reconstitution. Therefore, the availability of 
appropriately labeled 13C enzyme is severely limited. A step in the direction toward 
utilizing paramagnetic NMR as a tool for studying P450 is the development of a 
recombinant system whereby the P450 can be expressed with isotopically labeled heme 
incorporated, thus eliminating the need for inefficient reconstitution procedures.  
A strain of E.coli, Hu227 was selected because of its inability to produce 
aminolevulinic acid (ALA), a heme precursor in the biosynthetic pathway. Since E.coli 
Hu227 cannot synthesize their own ALA we can selectively label heme with isotopes by 
using isotopically labeled ALA in the media. In past studies, Cytochrome P450 has been 
expressed under the control of T7 promoter using E.Coli BL-21 cells. These cells have a 
T7 polymerase encoded in their genome, under the control of a lac promoter. Thus, IPTG 
addition involves T7 polymerase production which, in turn, induces the target gene. 
Hu227 cells have no such T7 polymerase, so expression of P450 from one of the readily 
available plasmids in Hu227 would be expected to be very inefficient. 
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 Dehaloperoxidase (DHP), an enzyme which also contains heme has been a model 
protein because it was under the control of lac promoter and expresses very well in these 
cells. An additional goal of this research, however remained improving expression of the 
P450BM3 enzyme in the Hu227 cells. Initially there was an attempt at a multi step 
synthesis of 2H-aminolevulinic acid from glycine, but the deuterium apparently 
exchanged with hydrogen from water in the last step. However, an alternative method 
was used to make 2H-aminolevulinic acid and it was characterized using 1H-NMR. 
Additionally, the generation of good expression level for both DHP and BM3F87G was 
conducted successfully. Also, the expression level for both unlabeled DHP and also 
isotopically labeled DHP was generated in a high yield.  
High performance liquid chromatography – mass spectrometry with electrospray 
ionization (LC-MS) was conducted on heme that had been extracted and purified from 
dehaloperoxidase. Previously, it was proven that 13C-ALA was incorporated into DHP 
and a clear 624 m/Z peak was shown. But, since there was no 624 m/Z peak in the current 
sample of DHP but a 616 m/Z was observed, another ionization method, MALDI-TOF 
was used in order to clarify the 616 m/Z of 13C-DHP. After eliminating the possibility of 
contamination, there was a clear 624 m/Z peak for 13C-DHP on MALDI. However, when 
comparing the MALDI-TOF spectrum of unlabeled heme sample to the 2H-labeled heme 
sample, there is no increase in mass 616 m/Z to 624 m/Z, which clearly indicates there 
was no incorporation 2H-labeled atoms in the heme. This might be due to hydrogen in 
56 
 
 
57 
 
water environment replacing deuterium in heme, or a slow exchange of hydrogen and 
deuterium through the enzymatic reaction of ALA to heme. Although it was not possible 
to incorporate 2H into the heme, successful incorporation of 13C and 15N into the heme 
will be useful in the application of the spectroscopic techniques when applied to P450 
enzymes. 
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